Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Non-Current Deffered Revenue (2016 - 2025)

Voyager Therapeutics' Non-Current Deffered Revenue history spans 11 years, with the latest figure at $1.5 million for Q3 2025.

  • For Q3 2025, Non-Current Deffered Revenue fell 87.9% year-over-year to $1.5 million; the TTM value through Sep 2025 reached $1.5 million, down 87.9%, while the annual FY2024 figure was $6.0 million, 81.45% down from the prior year.
  • Non-Current Deffered Revenue for Q3 2025 was $1.5 million at Voyager Therapeutics, down from $2.6 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $78.9 million in Q1 2023 and bottomed at $1.5 million in Q3 2025.
  • The 5-year median for Non-Current Deffered Revenue is $12.2 million (2024), against an average of $20.7 million.
  • The largest annual shift saw Non-Current Deffered Revenue skyrocketed 833.51% in 2023 before it tumbled 87.9% in 2025.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $8.2 million in 2021, then fell by 21.44% to $6.4 million in 2022, then surged by 401.69% to $32.4 million in 2023, then plummeted by 81.45% to $6.0 million in 2024, then crashed by 75.5% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Non-Current Deffered Revenue are $1.5 million (Q3 2025), $2.6 million (Q2 2025), and $4.8 million (Q1 2025).